[Clinical observation of immunotherapy in ocular malignant tumors with lymphokine-activated killing (LAK) cell].
In this paper, the authors reported the method of treating ocular malignant tumors with lymphokine-activated killing cells which were induced by rIL-2 in vitro. Among the sixteen cases of ocular tumors, 4 cases of 5 base cell carcinoma (1 case of which was partially extinctive), 4 cases of tarsal gland carcinoma, 2 cases of squamous cell carcinoma and respectively 1 case of retinoblastoma, non-Hodgkin's lymphoma, intraorbital hemangiopericytoma, intraorbital fibrous histiocytomas and hidradenocarcinoma were completely extinctive. The result shows that the immunotherapy method is effective.
Yang
L
L
Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University, Xian, China.
Wang
H
H
Zhang
X
X
Zhang
J
J
Liang
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D002280:Basal Cell Carcinoma / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005134:Eye Neoplasms / Q000628:therapy*; D005142:Eyelid Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008297:Male; D008537:Meibomian Glands; D008875:Middle Aged